Background Hepatitis B virus (HBV) is a common cause of viral hepatitis with significant health complications including cirrhosis and hepatocellular carcinoma. Assays for hepatitis B surface ...

Breakthrough therapy designation recognises the potential of brelovitug to transform the lives of people living with CHD. We look forward to initiating a global pivotal trial a ...

All students must have a series of three Hepatitis B vaccinations (0, 1, and 6 months), and a post-vaccine surface antibody titer (to ... must satisfy this requirement, either by a positive Varicella ...

The report highlighted that testing was conducted for the presence of Hepatitis B surface antigen (HBsAg) and antibodies to Hepatitis ... of individuals testing positive for Hepatitis B since ...

The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to brelovitug (BJT-778) for the treatment of chronic hepatitis delta (CHD).

A dot plot showing COI for the HBsAg test for all 34 patients who received hepatitis B vaccine 14 days or less before HBsAg testing is shown in Figure 3. There was one patient who had a positive ...